Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study

Huaguang Zheng, Hongwei Li, Yilong Wang, Zhanquan Li, Bo Hu, Xiaogang Li, Lu Fu, Hongtao Hu, Zhiyu Nie, Bilian Zhao, Di Wei, Björn W. Karlson, Michiel L. Bots, Xiang Wen Meng, Yundai Chen, Yongjun Wang*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Atherosclerosis is the leading cause of cardiovascular disease worldwide, including in China. Primary prevention, through lipid-lowering, could avert development of atherosclerosis. Carotid intima-media thickness (CIMT) is a well-validated measure of atherosclerosis used in intervention studies as the primary outcome and alternative end point for cardiovascular disease events. Methods: This randomized, double-blind, placebo-controlled, multicenter, parallel-group study assessed the effects of rosuvastatin 20 mg/d compared with placebo on progression of CIMT over 104 weeks in Chinese people with subclinical atherosclerosis. The primary end point was the annualized rate of change in mean of the maximum CIMT measurements taken 7× over the study period from each of 12 carotid artery sites (near and far walls of the right and left common carotid artery, carotid bulb, and internal carotid artery). Secondary end points included CIMT changes at different artery sites and lipid-parameter changes. Safety was also assessed. Results: Participants were randomized (1:1) to receive rosuvastatin (n=272) or placebo (n=271). Baseline characteristics were well balanced between groups. The change in mean of the maximum CIMT of the 12 carotid sites was 0.0038 mm/y (95% CI, -0.0023-0.0100) for the rosuvastatin group versus 0.0142 mm/y (95% CI, 0.0080-0.0204) for the placebo group, with a difference of -0.0103 mm/y (95% CI, -0.0191 to -0.0016; P=0.020). For the CIMT secondary end points, the results were generally consistent with the primary end point. There were clinically relevant improvements in lipid parameters with rosuvastatin. We observed an adverse-event profile consistent with the known safety profile of rosuvastatin. Conclusions: Rosuvastatin 20 mg/d significantly reduced the progression of CIMT over 2 years in Chinese adults with subclinical atherosclerosis and was well tolerated. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02546323.

Original languageEnglish
Pages (from-to)3004-3013
Number of pages10
JournalStroke
Volume53
Issue number10
DOIs
Publication statusPublished - Oct 2022

Keywords

  • Adult
  • Atherosclerosis/diagnostic imaging
  • Cardiovascular Diseases/drug therapy
  • Carotid Arteries/diagnostic imaging
  • Carotid Artery Diseases/diagnostic imaging
  • Carotid Intima-Media Thickness
  • Disease Progression
  • Fluorobenzenes/pharmacology
  • Humans
  • Lipids/pharmacology
  • Pyrimidines/pharmacology
  • Rosuvastatin Calcium/pharmacology
  • Sulfonamides/pharmacology

Fingerprint

Dive into the research topics of 'Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study'. Together they form a unique fingerprint.

Cite this